CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Stock Jumps 20 per cent in Single Day, Hits Upper Circuit as Microcap Company Secures Rs 17,13,01,433 Order from Rajasthan Medical Services Corporation!
DSIJ Intelligence

Stock Jumps 20 per cent in Single Day, Hits Upper Circuit as Microcap Company Secures Rs 17,13,01,433 Order from Rajasthan Medical Services Corporation!

FIIs increased their stake in the company in the recent quarter and currently hold 8.99 per cent stake.

Incorporated in 2015, Sotac Pharmaceuticals Ltd specializes in manufacturing pharmaceutical products under loan license or contract manufacturing agreements for various marketers.

Recently, Sotac Pharmaceuticals Ltd received a Letter of Acceptance amounting to approximately Rs 17,13,01,433 (including GST) from Rajasthan Medical Services Corporation Limited for the supply of diverse pharmaceutical products. The company is required to fulfill the order before March 31, 2025.

Share Performance:

Today Sotac Pharmaceuticals Ltd shares closed the day at Rs 144 per share. The company’s current market capitalization stands at Rs 159 crore. The stock has delivered a return of around 30 per cent in the past 6 months.

Financial performance:

According to the Quarterly Results, in Q4 FY24, Sotac Pharmaceuticals Ltd reported a revenue of Rs 52 crore and an operating profit of Rs 4 crore. The operating profit margin for the quarter stands at 8 per cent. The company’s net profit stood at Rs 3 crore. In FY24, the company reported a revenue of Rs 104 crore compared to Rs 77 crore, and a net profit of Rs 4 crore, compared to a profit of Rs 2 crore in the previous year.

As per the current shareholding pattern, promoters own 72.85 per cent, while FIIs and public investors own 8.99 per cent and 18.16 per cent, respectively.

Sotac Pharmaceuticals' manufacturing facility is situated at Sanand GIDC–II in Ahmedabad district. The company holds manufacturing permissions for 329 products under license number G/25/2169 and 45 products under license number G/28/1587 from the Food & Drug Department.

Investors must keep this micro-cap stock on their radar.

Disclaimer: The article is for informational purposes only and not investment advice.

DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.

Previous Article Multibagger penny stock at Rs 56: This civil construction company bags order worth Rs 7,39,74,233.12 from Government of Tripura
Next Article Vijay Kedia's portfolio civil construction stock delivers multibagger returns of 180 per cent in just 10 months with Rs 2,235 crore order book; do you own it?
Print
11630 Rate this article:
4.6
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR